...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Survival Impact of Postoperative Adjuvant Radiotherapy for Treatment of Advanced Stage Maxillary Sinus Cancer Patients
【24h】

Survival Impact of Postoperative Adjuvant Radiotherapy for Treatment of Advanced Stage Maxillary Sinus Cancer Patients

机译：术后辅助放疗对晚期上颌窦癌患者的生存影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Maxillary sinus cancer is a rare disease and usually present in advanced stage. Limited clinical data exists from India about the use of adjuvant radiotherapy in advanced cases and survival thereafter.Aim: To study survival and identify prognostic factors of importance in patients irradiated postoperatively for advanced stage maxillary sinus carcinoma.Materials and Methods: Medical records of 25 patients of advanced stage maxillary sinus carcinoma treated with curative intent from January 2011 to November 2016 were analysed retrospectively. All the patients underwent primary surgery followed by postoperative adjuvant radiotherapy. Survival analysis was done using Kaplan-Meier method.Results: All patients presented with advanced disease Stage III or IV; nodal involvement was observed in 5 (20%) patients. The three-year overall survival after surgery and postoperative radiotherapy with or without concurrent chemotherapy was 74%. Median survival was 17 months. Most common pattern of recurrence was at the primary site, observed in 5 (20%) patients. Lymph node involvement, pT4 lesion, surgical margins positive, depth of invasion >10 mm, high grade, lymphovascular/perineural invasion were prognostic factors of importance.Conclusion: Primary surgical treatment of maxillary sinus carcinoma in advanced stage followed by postoperative adjuvant radiotherapy is a good treatment option.
机译：上颌窦癌是一种罕见的疾病，通常存在于晚期。来自印度的关于在晚期病例中使用辅助放疗及其后存活的有限临床数据。目的：研究存活率并确定晚期上颌窦窦癌术后接受放射治疗的患者的重要预后因素。材料和方法回顾性分析2011年1月至2016年11月收治的25例晚期上颌窦癌患者的病历。所有患者均接受了一次外科手术，随后进行了辅助放疗。结果：所有患者均表现为晚期疾病III或IV期;所有患者均处于III期或IV期晚期。在5名（20％）患者中观察到淋巴结受累。手术或放疗后同时进行或未同时进行化疗的三年总生存率为74％。中位生存期为17个月。复发的最常见模式是在原发部位，在5名（20％）患者中观察到。预后因素重要。放射疗法是一个很好的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号